Clinical Trial

Baricitinib for the Lung Injury Following Spontaneous SAH

Study acronym: BLISS
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The present study is a randomized, parallel control, and double-blind trial designed to assess the efficacy of baricitinib in reducing the occurrence of pulmonary complications in patients with spontaneous subarachnoid hemorrhage (SAH). The research protocol incorporates an adaptive design, allowing for modifications to key elements such as the sample size enrolled during interim analysis.
Trial Details
NCT Number NCT06439615
Lead Sponsor Tang-Du Hospital
Conditions Spontaneous Subarachnoid Hemorrhage
Enrollment 100 participants
Start Date 2024-08-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-06-03